Read More

Combangio, Inc., A Wholly Owned Subsidiary Of Kala Pharmaceuticals, Awarded $15M By California Institute For Regenerative Medicine To Support Ongoing KPI-012 Program For The Treatment Of Persistent Corneal Epithelial Defect

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today

KALA